Otsuka’s Sibeprenlimab Shows Promising Results in IgAN Treatment

Tip Ranks
2025.11.09 23:52
portai
I'm PortAI, I can summarize articles.

Otsuka Holdings Co. announced promising 12-month interim results from its Phase 3 VISIONARY trial for sibeprenlimab, a treatment for immunoglobulin A nephropathy (IgAN), showing significant reduction in proteinuria and a favorable safety profile. The company has filed a Biologics License Application with the U.S. FDA, receiving a Priority Review designation. The latest analyst rating for Otsuka's stock (JP:4578) is a Buy with a price target of Yen9366.00. Current market cap stands at Yen4415.6B, with a year-to-date price performance of -1.84%.

Meet Your ETF AI Analyst

  • Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
  • Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.

Otsuka Holdings Co ( (JP:4578) ) has shared an update.

Otsuka Holdings Co. announced promising 12-month interim results from its Phase 3 VISIONARY trial for sibeprenlimab, a treatment for immunoglobulin A nephropathy (IgAN). The trial showed a significant reduction in proteinuria, a marker for kidney disease progression, with a favorable safety profile. The company has filed a Biologics License Application with the U.S. FDA, receiving a Priority Review designation, which could enhance its market position in nephrology treatments.

The most recent analyst rating on (JP:4578) stock is a Buy with a Yen9366.00 price target. To see the full list of analyst forecasts on Otsuka Holdings Co stock, see the JP:4578 Stock Forecast page.

More about Otsuka Holdings Co

Otsuka Holdings Co., Ltd. operates in the pharmaceutical industry, focusing on innovative treatments and healthcare solutions. The company is known for developing novel drugs and therapies, with a market focus on addressing unmet medical needs.

YTD Price Performance: -1.84%

Average Trading Volume: 1,116,386

Technical Sentiment Signal: Strong Buy

Current Market Cap: Yen4415.6B

Find detailed analytics on 4578 stock on TipRanks’ Stock Analysis page.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.